Fulgent Genetics Inc

Fulgent Genetics Inc. together with its subsidiaries provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services such as gastrointestinal pathology dermatopathology urologic pathology breast pathology neuropathology and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer cardiovascular genetics reproductive health and neurodegenerative genetics as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile or PK profile of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes data suppression and comparison algorithms adaptive learning software and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance hospitals medical institutions other laboratories governmental bodies payors municipalities and large corporations and patients. The company was formerly known as Fulgent Diagnostics Inc. and changed its name to Fulgent Genetics Inc. in August 2016. Fulgent Genetics Inc. was founded in 2011 and is headquartered in Temple City California.